Monte Rosa Therapeutics, Inc. Board of Directors

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Dr. Markus Warmuth M.D.

Dr. Markus Warmuth M.D.

President, CEO & Director

Dr. Sharon Townson Ph.D.

Dr. Sharon Townson Ph.D.

Chief Scientific Officer

Ms. Jennifer Champoux

Ms. Jennifer Champoux

Chief Operating Officer

Mr. Edmund Dunn

Mr. Edmund Dunn

Vice President & Corporate Controller

Dr. John C. Castle Ph.D.

Dr. John C. Castle Ph.D.

Chief Data & Information Officer

Mr. Andrew Funderburk

Mr. Andrew Funderburk

Senior VP and Head of IR & Strategic Finance

Mr. Philip Nickson J.D., Ph.D.

Mr. Philip Nickson J.D., Ph.D.

Chief Business & Legal Officer

Mr. Magnus Walter DPHIL

Mr. Magnus Walter DPHIL

Senior Vice President of Drug Discovery

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.